Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.

Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown AL, Goncearenco A, Panchenko AR, Biswas R, Thomas A, Rajan A, Carter CA, Kleiner DE, Hewitt SM, Khan J, Prokunina-Olsson L, Guha U.

Cell Rep. 2019 Mar 5;26(10):2651-2666.e6. doi: 10.1016/j.celrep.2019.02.028.

2.

Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.

Zhang X, Nguyen KD, Rudnick PA, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro CM, Fenyö D, Guha U.

Mol Cell Proteomics. 2019 Apr;18(4):622-641. doi: 10.1074/mcp.RA118.001266. Epub 2019 Jan 7.

PMID:
30617155
3.

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.

Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Charles Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U.

Mol Cell Proteomics. 2017 May;16(5):891-910. doi: 10.1074/mcp.M117.067439. Epub 2017 Mar 22.

4.

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U.

Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001263.

5.

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.

Venugopalan A, Lee MJ, Niu G, Medina-Echeverz J, Tomita Y, Lizak MJ, Cultraro CM, Simpson RM, Chen X, Trepel JB, Guha U.

Oncotarget. 2016 Aug 23;7(34):54137-54156. doi: 10.18632/oncotarget.11021.

6.

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.

Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U.

Cancer Discov. 2015 May;5(5):534-49. doi: 10.1158/2159-8290.CD-14-0750. Epub 2015 Mar 3.

7.

Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma.

Meerzaman DM, Yan C, Chen QR, Edmonson MN, Schaefer CF, Clifford RJ, Dunn BK, Dong L, Finney RP, Cultraro CM, Hu Y, Yang Z, Nguyen CV, Kelley JM, Cai S, Zhang H, Zhang J, Wilson R, Messmer L, Chung YH, Kim JA, Park NH, Lyu MS, Song IH, Komatsoulis G, Buetow KH.

Cancer Genomics Proteomics. 2014 Jan-Feb;11(1):1-12.

PMID:
24633315
8.

Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma.

Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, Cultraro CM, Finney RP, Kelley JM, Efroni S, Greenblum SI, Nguyen CV, Rowe WL, Sharma S, Wu G, Yan C, Zhang H, Chung YH, Kim JA, Park NH, Song IH, Buetow KH.

Hepatology. 2010 Dec;52(6):2034-43. doi: 10.1002/hep.23943.

PMID:
21105107
9.

Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms.

Zingone A, Cultraro CM, Shin DM, Bean CM, Morse HC 3rd, Janz S, Kuehl WM.

Leukemia. 2010 Jun;24(6):1171-8. doi: 10.1038/leu.2010.50. Epub 2010 Apr 15.

10.

Mad1 function is regulated through elements within the carboxy terminus.

Barrera-Hernandez G, Cultraro CM, Pianetti S, Segal S.

Mol Cell Biol. 2000 Jun;20(12):4253-64.

11.

Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression.

Casalini P, Ménard S, Malandrin SM, Rigo CM, Colnaghi MI, Cultraro CM, Segal S.

Int J Cancer. 1997 Aug 7;72(4):631-6.

12.
13.

Regulated expression and function of the c-Myc antagonist, Mad1, during a molecular switch from proliferation to differentiation.

Cultraro CM, Bino T, Segal S.

Curr Top Microbiol Immunol. 1997;224:149-58. Review. No abstract available.

PMID:
9308238
14.

c-Myc inactivation by mutant Max alters growth and morphology of NCI-H-630 colon cancer cells.

Borrè A, Cultraro CM, Segal S.

J Cell Physiol. 1996 Oct;169(1):200-8.

PMID:
8841436
15.

Regulation of murine Max (Myn) parallels the regulation of c-Myc in differentiating murine erythroleukemia cells.

Dunn BK, Cogliati T, Cultraro CM, Bar-Ner M, Segal S.

Cell Growth Differ. 1994 Aug;5(8):847-54.

16.

Transfected wild-type and mutant max regulate cell growth and differentiation of murine erythroleukemia cells.

Cogliati T, Dunn BK, Bar-Ner M, Cultraro CM, Segal S.

Oncogene. 1993 May;8(5):1263-8.

PMID:
8479748
17.

Supplemental Content

Loading ...
Support Center